Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY

 | Aug 15, 2019 11:28PM ET

This week, the FDA granted approval to Roche’s (OTC:RHHBY) tumor-agnostic medicine, Rozlytrek (entrectinib), and J&J’s (NYSE:JNJ) tuberculosis tablet Sirturo for adolescent patients. Meanwhile, Lilly (NYSE:LLY) and AstraZeneca (NYSE:AZN) announced data from studies on psoriasis drug Taltz and cancer drugs Tagrisso and Lynparza, respectively.

Recap of the Week’s Most Important Stories

Roche’s Personalized Medicine Rozlytrek Gets FDA Nod: The FDA granted approval to Roche’s personalized medicine Rozlytrek (entrectinib) for patients with ROS1-positive, metastatic non-small cell lung cancer (NSCLC) and neurotrophic tyrosine receptor kinase (NTRK) fusion-positive, advanced recurrent solid tumors. Per Roche, Rozlytrek is the first tumour-agnostic medicine to be approved in the United States that selectively targets both ROS1 and NTRK fusions. Rozlytrek has also shown responses in these two rare types of cancer that have spread to the brain. Japan was the first country to grant approval to Rozlytrek in June.

J&J’s Sirturo Gets FDA-Approved for Young TB Patients: J&J’s pulmonary multidrug-resistant Large Cap Pharmaceuticals Industry 5YR % Return

Here is how the seven major stocks performed in the last five trading sessions.